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Serological testing for anti-neural autoantibodies is important in patients presenting with idiopathic cerebellar
ataxia, since these autoantibodies may indicate cancer, determine treatment and predict prognosis. While some of
them target nuclear antigens present in all or most CNS neurons (e.g. anti-Hu, anti-Ri), others more specifically
target antigens present in the cytoplasm or plasma membrane of Purkinje cells (PC). In this series of articles, we
provide a detailed review of the clinical and paraclinical features, oncological, therapeutic and prognostic implications,
pathogenetic relevance, and differential laboratory diagnosis of the 12 most common PC autoantibodies (often referred
to as ‘Medusa head antibodies’ due to their characteristic somatodendritic binding pattern when tested by
immunohistochemistry). To assist immunologists and neurologists in diagnosing these disorders, typical high-resolution
immunohistochemical images of all 12 reactivities are presented, diagnostic pitfalls discussed and all currently available
assays reviewed. Of note, most of these antibodies target antigens involved in the mGluR1/calcium pathway
essential for PC function and survival. Many of the antigens also play a role in spinocerebellar ataxia. Part 1 focuses
on anti-metabotropic glutamate receptor 1-, anti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate
receptor- and anti-carbonic anhydrase-related protein VIII-associated autoimmune cerebellar ataxia (ACA); part 2
covers anti-protein kinase C gamma-, anti-glutamate receptor delta-2-, anti-Ca/RhoGTPase-activating protein 26- and
anti-voltage-gated calcium channel-associated ACA; and part 3 reviews the current knowledge on anti-Tr/delta
notch-like epidermal growth factor-related receptor-, anti-Nb/AP3B2-, anti-Yo/cerebellar degeneration-related
protein 2- and Purkinje cell antibody 2-associated ACA, discusses differential diagnostic aspects and provides a
summary and outlook.
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GRAF) antibodies, Glutamate receptor delta2 (GluRδ2) antibodies, Anti-Yo, Cerebellar degeneration-related
protein 2 (CDR2) antibodies, Cerebellar degeneration-related protein 2-like (CDR2L) antibodies, Purkinje cell
antibody 2 (PCA-2), Anti-Tr, Delta notch-like epidermal growth factor-related receptor (DNER) antibodies, Anti-Nb,
Anti-AP3B2, Neuronal adaptin-like protein (beta-NAP) antibodies, Voltage-gated calcium channel (VGCC) antibodiesIntroduction
Autoimmune cerebellar ataxia (ACA) represents an im-
portant differential diagnosis in patients presenting with
signs and symptoms of cerebellar disease. Alongside mul-
tiple sclerosis and acute disseminated encephalomyelitis,
autoantibody-associated disorders of the central nervous
system (CNS) are the most common cause of ACA. While
ACA is a rare manifestation in some antibody-related
disorders, such as in aquaporin-4 (AQP4) antibody-
associated neuromyelitis optica (NMO), it is the most
frequent or exclusive presentation in others. To date,
around 30 different autoantibodies targeting brain anti-
gens have been reported in patients with ACA, many of
which are of paraneoplastic origin.
When tested by immunohistochemistry (IHC) using
cerebellum tissue sections, 12 of those antibodies show a
staining pattern resembling a Gorgon head caused by
binding of IgG to Purkinje cell (PC) somata and den-
drites and are therefore often referred to as ‘Medusa
head’ antibodies. Most of these antibodies are involved
in regulating calcium homoeostasis in PCs.
In part 1 of this series of articles, we focused on anti-
metabotropic glutamate receptor 1 (mGluR1)-, anti-
Homer protein homolog 3 (Homer-3)-, anti-Sj/inositol
1,4,5-trisphosphate receptor (ITPR1)- and anti-carbonic
anhydrase-related protein VIII (CARP VIII)-associated
ACA [1]. The second part covered anti-protein kinase
C gamma (PKCγ)-, anti-glutamate receptor delta-2
(GluRδ2)-, anti-Ca/RhoGTPase-activating protein 26
(ARHGAP26)- and anti-voltage-gated calcium channel
(VGCC)-associated ACA [2]. In the present, third part
of our article series, we focus on anti-Tr/delta notch-
like epidermal growth factor-related receptor (DNER)-,
anti-Nb/AP3B2-, anti-Yo/cerebellar degeneration-related
antigen 2 (CDR2)-, anti-cerebellar degeneration 2-like
(CDR2L)- and Purkinje cell antibody 2 (PCA-2)-positive
ACA, discuss diagnostic pitfalls and present a summary
and outlook.
Anti-Yo/CDR2/CDR62 (PCA-1)
Clinical, paraclinical and epidemiological features
Anti-Yo antibodies were first reported by Greenlee and
Brashear in two patients with paraneoplastic cerebellar
degeneration (PCD) in 1983 [3]. Since then, hundreds of
cases have been identified, rendering anti-Yo one of the
most common paraneoplastic antibodies. Clinically,
most patients present with a subacute and mostly severepancerebellar syndrome with truncal and appendicular
ataxia, dysarthria and (mostly downbeat) nystagmus;
other signs and symptoms may be present, with mild
long-tract involvement, peripheral neuropathy, dyspha-
gia, diplopia, vertigo and cognitive impairment being the
most common ones [4]. Median age at onset is 61 years
(range, 26–85) [4]. Almost all patients are female,
though a few male patients have been described [5–9].
MRI often shows cerebellar atrophy after some weeks
or months but may be normal at disease onset (17/55
cases in reference [4]). CSF often shows lymphocytic
pleocytosis, oligoclonal bands, an increased CSF/serum
ratio and elevated total protein levels [4, 10].
Tumour association
Anti-Yo antibodies are usually associated with malignant
gynaecological tumours (ovary, breast, mesovarium, fal-
lopian tube, uterus or cervix), which are often confined
to the involved organs or local lymph nodes [4]. Rarely,
other tumours have been found, including lung cancer
[4]. In the few male anti-Yo-positive patients, PCD was
associated with adenocarcinomas (prostate, esophagus,
stomach or intestine) [5–9].
In the majority of patients, the onset of PCD precedes
the tumour diagnosis by months or even years [4]; ac-
cordingly, regular screening for malignant tumours is re-
quired in confirmed, positive cases without tumour at
first presentation [11]. Sometimes, carcinomas remain oc-
cult and are detected only upon autopsy, possibly due to
an effective anti-Yo-related anti-tumour immune re-
sponse and, though rarely, no tumour is found [4]. In
the latter case, preventive hysterectomy and salpingo-
ovarectomy have been proposed [12] if symptoms are se-
vere and do not respond to treatment and provided the
positive test result has been confirmed in a second assay.
Anti-Yo antibodies were absent in patients with ovar-
ian or breast cancer but no neurological symptoms in
one study (n = 79) [4] but were found in a small subset
of patients (~2 %) in another one [13]. Anti-Yo was not
detected in 150 control subjects who had neither PCD
nor cancer [4, 14].
Outcome and prognosis
Given that the disease usually takes a subacute, rapidly
progressive course, which often results in complete loss
of PCs and, accordingly, substantial disability within
weeks or a few months, early treatment is crucial.
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management. Immunosuppression has mostly no or only
minor effect [4, 15, 16], although PEX, IVIG, rituximab,
steroids and cyclophosphamide were reportedly beneficial
in some cases [17–20], especially if treatment was initiated
shortly after disease onset.
Peterson et al. [4] found that 37 out of 48 assessable
patients were unable to walk or sit unassisted at final
follow-up. The median survival time in anti-Yo-positive
patients is 22 months; however, long-term survival (up
to 164 months) has been reported, too [15]. Prognosis
may also be determined by the type of the underlying
tumour, with breast cancer patients having a better prog-
nosis [15]. PCD rather than tumour progression is the
cause of death in around 40 % [15].
Antigen
Anti-Yo-positive sera recognize CDR2 (cerebellar
degeneration-related 2; less commonly termed CDR62),
a 62-kDa protein with a helix leucine zipper (HLZ) and
a zinc finger motif [21, 22] that is widely expressed in
gynaecological tumours [23] but mainly restricted to
cerebellum (Fig. 1), brainstem. In healthy tissue it is
mainly restricted to cerebellum, brainstem and testis
[24–26] and testes in healthy tissue [24–26]. The anti-
bodies partly target the leucine zipper motif of CDR2,Fig. 1 Expression of CDR2 in the human cerebellum as demonstrated by IHgiving rise to the possibility of cross-reactivity with pro-
teins containing such a motif [27]. At lower magnitude
and inconstistently, anti-Yo-positive sera were shown to
recognize a second, 34-kDa onconeuronal protein in
cerebellum or PC Western blots which contains a
unique six amino acid (aa) consensus sequence (L/
FLEDVE) [28–30].
Moreover, anti-Yo sera have been reported to bind to
CDR3 [31], a protein similar to CDR2, and, in 85 %, to
CDR2L (cerebellar degeneration-related 2-like) [14, 32].
CDR2L is expressed in PCs at a higher level than CDR2
[14] and has been detected in a variety of human tumours
[14, 33], including ovarian and breast cancer cells.
Immunohistochemistry
The antibody stains the cytoplasm of the PC somata in a
typical coarse, granular pattern and spares the nucleus.
Depending on titres, tissue donor species and fixation
and staining methods, additional binding to the PC den-
dritic arbour and, weakly, the peripheral PC dendritic
branches can be observed (Fig. 2) [3, 34–36]. However,
no axonal staining is observed. In addition, neurons in
the deep cerebellar nuclei are strongly stained by anti-Yo
in human tissue [34, 36].
According to our experience and that of other groups
[31], PCs are the main antibody target. However,C (modified image from the Human Protein Atlas image database [33])
Fig. 2 Binding of anti-Yo (PCA-1) from a patient with ACA to a mouse cerebellum tissue section. The patient antibody was detected by use of a
goat anti-human IgG secondary antibody labelled with Alexa Fluor@488 (green)
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and stellate neurons by anti-Yo-positive sera has been
reported [36].
Outside the cerebellum, binding to (large, cytoplasm-
rich) neurons in the brain, brainstem, retina, anterior
horns, sensory and sympathetic ganglia, and the my-
enteric plexus has been observed as well as staining of
the cytoplasm of Schwann cells [34, 37].
At the subcellular level, anti-Yo was found to bind to
clusters of ribosomes, orderly arrays of stacked parallel
cisternae of the granular endoplasmic reticulum and the
trans-face of the vesicles of the Golgi complex in the
perikaryon and dendritic processes of PCs [38]. A second
study found reactivity to both the rough and smooth
endoplasmic reticulum and polyribosomes in human andrat cerebellar Purkinje cells, other neuron cell bodies and
Schwann cells [39], while a third study reported immuno-
staining of free and membrane-bound ribosomes, but not
of the endoplasmic reticulum lumen, smooth endoplasmic
reticulum, Golgi complex, mitochondria or nucleus [40].
Whether these minor discrepancies were caused by meth-
odological differences among studies or due to different
antigen or epitope specificities between the respective pa-
tients is unclear. Outside the CNS, staining of the adrenal
medulla and of epithelial cells of the renal glomerulus has
been observed [34].
Antigen-specific assays
Numerous commercial and in-house assays are available,
including line or dot immunoblot (IB) assays, ELISAs,
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(CBAs). Most immunoassays use exclusively the major
antigen CDR62 as test substrate since the minor 34-kDa
reactivity is associated with CDR62 in all cases. System-
atic studies comparing the different assays are currently
lacking but are warranted. Storstein et al. [41] reported
higher sensitivity of an anti-CDR2-specific IP assay than
of an IB and a fluorescence-based IHC assay, but also a
lower specificity. The same group also found a higher
sensitivity of IP for detecting anti-CDR2L [14]. CDR2-
and a CDR2L-specific CBAs (Euroimmun, Luebeck,
Germany) are available at the authors’ institution for use
in scientific studies.
CSF testing
Stich et al. found evidence for intrathecal IgG synthesis,
as indicated by an elevated antibody index in 5/5 pa-
tients with anti-Yo-associated PCD [10, 42]. In a previous
study, 9/9 patients with PCD and anti-Yo serum anti-
bodies were found to have CSF-restricted CDR2-specific
oligoclonal bands [10].
Association with other autoantibodies
Anti-Yo are not typically associated with other well-
established paraneoplastic anti-CNS antibodies. However,
a single study reported antibodies to 20S proteasome
proteins in 8/14 patients with anti-Yo-positive PCD
[43], and a second one found antibodies to an uncharac-
terized protein called coiled-coil domain-containing
protein 104 (CCDC104) in around 10 % of anti-Yo-
positive patients [44]. However, the clinical relevance of
these co-reactivities is currently unknown.
Pathogenetic relevance
Pathologically, anti-Yo-positive PCD is characterized by
a massive loss in PCs, which can be accompanied by re-
active Bergman cell gliosis [45, 46]. In some, but not all
cases—possibly depending on the time between onset
and autopsy or biopsy [47]–, immune cell infiltrates are
present [45, 46]. Cell types reported included both T and
B cells, plasma cells and macrophages/microglial cells
[31, 46]. In accordance with the fact that CDR2 is also
expressed outside the cerebellum, inflammatory infil-
trates have been observed in the medulla, pons and/or
cerebrum (partly symptomatic [48]) as well as axonal
loss in the spinal cord [45, 47]. In the few cases exam-
ined histopathologically, no anti-Yo antibodies could be
detected at the lesion site. Given the rapid loss of PCs, it
is possible that these examples of ‘non-inflammatory PC
degeneration’ represent final burn-out stages [4]. This
would also explain the lack of immunoglobulin and
complement deposits found in some studies [45, 46].
The currently most widely accepted pathogenetic sce-
nario is that the ectopic expression of CDR2 in tumourtissue results in loss of immunotolerance against that
protein, resulting in secondary damage of neurons natur-
ally expressing CDR2, which is mediated by onconeuro-
nal antibodies and sensitized T cells [31, 49].
The exact mechanism by which anti-Yo could cause
PC damage is unclear. Anti-Yo mainly belong to the
complement-activating subclass 1 (rarely, IgG2, IgG3,
IgM or IgA anti-Yo antibodies are present) [50–53] and
are produced intrathecally [10, 42]. However, CDR2 is be-
lieved to be a mainly cytoplasmic protein not present in
the membrane and thus not accessible to circulating IgG
[38, 40]. By contrast, CDR2L, which has recently been
proposed to be an additional target antigen of anti-Yo,
is, at least in transfected HeLa cells, membrane bound
according to one study [14]. This would be of particular
interest given that Eichler et al. [14] found PCD only in
anti-Yo patients who reacted both to CDR2 and
CDR2L. However, it is not known to date whether
CDR2L is membrane linked in PCs in vivo as well. Of
note, Rodriguez et al. [38] found binding of anti-Yo-
like antibodies from patients with gynaecological
tumours to patches of external plasma membrane by
electron microscopy and discussed whether the antigen
might transiently reach the plasma membrane via the
Golgi complex or by being incorporated in synapto-
somes. However, at the time of testing, the target anti-
gen of anti-Yo was unknown and no Western blot data
was provided [38].
Alternatively, intracellular uptake of anti-Yo by PCs
could cause pathogenic effects. Viable PCs have been
demonstrated to internalize and accumulate serum,
CSF or purified anti-Yo in slice (organotypic) culture
experiments as well as in live animals after blood
barrier disruption or direct injection into the brain
[54–58]. By contrast, control IgG was reported to be
rapidly cleared from PCs [56, 57]. Incorporation of
myeloma light chains by PCs suggests that human neu-
rons might be able to incorporate IgG as well [59].
Interestingly, in one study, the uptake of IgG could be
blocked by colchicine [14].
While Greenlee et al. [57] found that intracellular ac-
cumulation of anti-Yo, but not of normal IgG, was
followed by PC death after 72–144 h without comprising
other cells, no cell death was observed in two previous
studies [54, 55]. However, differences in observation
times after IgG injection and detection methods might
account for that discrepancy [57].
Intracellular anti-IgG could theoretically disturb CDR2-
or CDR2L-dependent pathways. CDR2 contains leucine
zipper and zinc finger motifs as commonly found in
transcription factors and could thus influence protein
expression [22]. Of note, CDR2 has been shown to co-
localize and co-precipitate with c-Myc, which regulates
the expression of more than 10 % of all genes by binding
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acetyltransferases and has, thus, been implicated in im-
portant cell functions, including cell cycle progression
and apoptosis. In vitro, anti-Yo sera were shown to
block the interaction of the two proteins, preventing
CDR2-mediated down-regulation of c-Myc-dependent
transcription and of sequestration of c-Myc in the
neuronal cytoplasm, a mechanism that could lead to PC
death by apoptosis [60, 61]. In addition, CDR2 has been
implicated in inhibiting NFBκB-dependent transcription
in neurons [62] and proposed to regulate the nuclear
helix-loop-helix leucine zipper protein MRGX, which
has been implicated in cell growth, DNA repair, cell
ageing and apoptosis. Overexpression of MRGX in
T98G glioblastoma cells led to morphological changes
and cell death, which could be prevented by CDR2 [27].
On the other hand, two recent studies did not find signs
of apoptosis following anti-Yo uptake by PCs using
TUNEL (TdT-mediated dUTP-biotin nick end labelling)
and active cleaved caspase-3 staining [32, 57].
An immune electron microscopy study suggested
localization of the anti-Yo antigen on the ribosome and
thus regulation of protein synthesis rather than gene
expression in the nucleus [40].
A recent study investigated the pathological role of
CDR antibodies on calcium homeostasis in PCs using
cerebellar organotypic slice cultures [32]. In accordance
with previous studies, the authors found that PCs
rapidly incorporated anti-Yo. Interestingly, this was
associated with up-regulation of calcium-dependent
PKCγ and the voltage-gated calcium channel Cav2.1,
two other autoantigens in PCD, and of the calcium-
dependent protease calpain-2 (calpains have been in-
volved in LTD and apoptosis). It was also associated with
down-regulation of the cytoplasmic calcium-buffering
protein calbindin D28K and of the P/Q-type (VGCC)-
modulating PC-specific protein 2 (L7) [32]. Moreover,
CDR2 and calbindin were found to co-immunoprecipitate
[32]. Morphologically, anti-Yo uptake was associated with
reduced dendritic PC arborizations [32]. Anti-Yo could
thus exert pathogenic effects by dysregulating cell cal-
cium homeostasis, which would provide a rationale for
neuroprotective therapies.
However, passive transfer experiments with anti-Yo
injected intraventricularly or into the brain parenchyma
have not been successful thus far [54, 58, 63]. Similarly,
active immunization experiments with recombinant Yo
fusion protein [64] or cDNA [65] resulted in the produc-
tion of anti-CDR2 antibodies but neuronal damage was
not observed.
This has led to the notion that PCD is mainly caused
by T lymphocytes. PCs do express MHC class I and
could thus present CDR2 peptides [66]. Indeed, Albert
et al. [67] detected expanded populations of majorhistocompatibility complex class I-restricted CDR2-
specific, cytotoxic T lymphocytes (CTLs) in the blood
of three PCD patients using primary human cells in a
recall assay. A potent CTL response could also be elic-
ited by cross-presentation of apoptotic HeLa cells used as
a source of CDR2 by dendritic cells. The presence of
CDR2-reactive CTLs in patients with PCD was confirmed
in several [49, 68, 69], yet not all [70], studies. Of note, T
cells transfected with the respective, CDR2-specific T-cell
receptors were shown to be capable of destroying tumour
cells [69]. A role of regulatory T-cell dysfunction has been
proposed [71].
On the other hand, CDR2-specific CTLs were not found
in all studies [70, 72] and CDR2-specific T cells induced
by active immunization with cDNA as well as transfer of
lymphocytes from patients with anti-Yo-associated PCD
did not cause PC damage in two studies [58, 65].Molecular genetics
To date, no mutations in the CDR2 and CDR2L genes
have been described in patients with SCA.Anti-Nb/AP3B2 (beta-NAP)
Clinical, paraclinical and epidemiological features
In 1989, Darnell and colleagues reported on a PC antibody
in a 35-year-old woman with a subacute pancerebellar
syndrome developing over 1 week and no tumour at the
time of testing [73, 74]. The patient presented with severe
and incapacitating truncal and appendicular ataxia,
titubation of the head and trunk at rest and nystagmus.
The disease rendered her bedridden within 2 months.
According to the authors, the cerebellar syndrome
could not be distinguished from that seen with anti-Hu-
or anti-Yo-positive PCD.
Extracerebellar symptoms included diffuse hyperre-
flexia with bilateral extensor plantar responses. Formal
neuropsychiatric testing did not reveal any cognitive im-
pairment. Neither CSF analysis (3 white cells/μl; normal
protein; no OCBs) nor brain and spinal cord MRI re-
vealed pathological findings.Tumour association
In the only patient reported thus far, no tumour was de-
tected at last follow-up [74]; however, the patient had a
history of hysterectomy and salpingo-oophorectomy [31].Outcome and prognosis
The patient was still alive 3 years after disease onset, i.e.
at last follow-up, but was unable to stand or sit and to
feed or wash herself. Apparently, no immunotherapy
had been tried [74].
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In Western blots employing human PC and cerebellar
cortex protein extracts, respectively, the patient’s serum
IgG was found to recognize three bands of approximately
150, 120 and 65 kDa. Of note, binding of IgG to a band
migrating at precisely the same molecular weight as
the 150-kDa PC protein was detected in a Western
blot analysis of tumour cell lines (SCLC, melanoma,
neuroblastoma), leaving the possibility of a paraneo-
plastic syndrome caused by an occult neuoectodermal
tumour.
The target antigen was later identified as a neuron-
specific vesicle coat protein, named neuronal adaptin-
like protein (beta-NAP) [75] and now termed AP3B2
(see Fig. 3 for expression of AP3B2 in the human cere-
bellum). Beta-NAP forms part of the adaptor complex 3
(AP3). AP3 is a heterotetramer consisting of two large
adaptins (AP3D1 and AP3B2, or AP3B1), a medium
adaptin (AP3M1 or AP3M2) and a small adaptin (APS1
or AP3S2). Two variants of AP3 exist, the ubiquitously
expressed AP3A and the neuron-specific AP3B. AP3B
has been implicated in the normal formation and function
of some synaptic vesicles. Only the neuronal form is cap-
able of forming synaptic vesicles from endosomes [76].
Mice lacking the μ3B subunit of AP3B morphologicallyFig. 3 Expression of AP3B2 in the human cerebellum as demonstrated b
database [33])show synaptic abnormalities and functionally impaired
GABA release due to a reduction in vesicular GABA
transporter [77]. They also present with compromised
synaptic zinc stores and synaptic vesicle targeting of
membrane proteins involved in zinc uptake (ZnT3 and
ClC-3) [78] These findings suggest that AP3B is involved
in controlling the levels of selected membrane proteins in
synaptic vesicles. Grabner et al. [79] found a correlation
between AP3B expression levels in neurons and the
neurotransmitter content of individual vesicles as well as
with dense-core vesicle size, providing additional evidence
for a role of AP3 in neurotransmitter release; the authors
located AP3 to the trans-Golgi network and immature
secretory vesicles and proposed that the protein is in-
volved in the formation of neurosecretory vesicles.
Of note, beta-NAP transmigrates to the membrane
during calcium influx in neurons, linking its subcellular
expression profile to intracellular calcium levels and thus
to the other antigens discussed in this section [75].
Immunohistochemistry
As with anti-Hu, anti-Ri, and anti-Ca, the immunofluor-
escence pattern was named after the index patients’ ini-
tials or code (Nb). In an avidin-biotin peroxidase IHC
assay employing frozen sections of human cerebellum,y IHC (modified image from the Human Protein Atlas image
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also to the molecular layer [74]. The antibody reacted
with the cytoplasm and nucleoli of PCs, while anti-Hu
spared the nucleoli. In contrast to the coarse staining
usually seen with anti-Yo, anti-Nb diffusely stained the
PC cytoplasm [74, 75]. In addition, anti-Nb caused low-
level diffuse staining of the cortex and intense staining
of very rare cells in the granular and molecular layer in
that study. In the cerebral cortex, the antibody predom-
inantly reacted with neurons in layer VI with only little
fluorescence in layer I, while no such gradient was
found with anti-Hu.
A follow-up study by Newman et al. [75] also found
reactivity of PC somata and processes. In addition to
PCs and cortical neurons, the authors reported high-
level expression of beta-NAP in hippocampal neurons,
too [75]. No expression in glial cells or in cells outside
the CNS was observed.Antigen-specific assays
No beta-NAP-specific immunoassays have been pub-
lished thus far.CSF testing
Anti-Nb were present in the index case at a titre of
1:5000 in the serum and at a titre of 1:100 in the CSF.
Similar results were obtained in WB assays of human
PCs and human cerebral cortex, respectively (serum
1:1000; CSF 1:100). Given the reportedly normal CSF
analysis (including normal protein levels), the relatively
high CSF titres as compared to serum are indicative of
possible intrathecal anti-Nb synthesis (negative total-IgG
OCBs do not exclude intrathecal synthesis of specific
autoantibodies [42, 80–84]).Association with other autoantibodies
In the index patient, anti-Nb was associated with an in-
crease in circulating immune complexes, but no further
co-existing autoantibodies were reported [74].Pathogenetic relevance
The pathogenetic relevance of anti-Nb has not been inves-
tigated yet. Darnell et al. [74] described a cytoplasmic or
membrane location of the target antigen. Newman et al.
indeed proposed temporary membrane recruitment of
beta-NAP from cytoplasmic pools in the nerve termi-
nals and cell body via endosome-derived vesicles upon
neuronal depolarization-related calcium influx [75].
Whether this would render beta-NAP accessible to
extracellular antibodies seems unlikely, however, since
the predicted protein sequence does not contain a
transmembrane domain.Molecular genetics
While mutations in the beta-NAP gene have not been
reported in patients with cerebellar ataxia so far,
ataxia-telangiectasia is caused by mutations in the
beta-NAP-interacting ATM protein [85]. Given that
the index patient presented with hyperreflexia and a
positive Babinski reflex, it is of note that mutations in
beta-NAP have been proposed to play a role in spastic
paraplegia-6 [86].
Antibodies to unknown antigens or to antigens
not related to the glutamate/calcium pathway
Two autoantibodies have been described in patients
with ACA that recognize PC somata and dendrites but
are not known to affect the glutamate/calcium pathway:
PCA-2 [35], the target antigen of which is unknown,
and anti-Tr, which has recently been shown to target
DNER [87].
PCA-2
Clinical, paraclinical and epidemiological features
So far, nine patients with PCA-2 and neurological
symptoms have been reported (7 women, 2 men; age:
44–73 years) [35]. Of note, only three of those patients
had predominant cerebellar ataxia (2 women, 1 man;
age 44, 66 and 73). Symptoms in those patients in-
cluded wide-based gait, limb ataxia, dysarthria, loss of
fine motor control and intention tremor; in one patient,
who was also positive for CV2/CRMP5 and neuronal
acetylcholine receptor (AChR) antibodies, ataxia was
accompanied by dysphagia and constipation [35].
The remaining six patients presented with predominant
limbic or brainstem encephalitis, autonomic neuropathy,
motor neuropathy, Lambert Eaton myasthenic syndrome
and/or syndrome of inappropriate antidiuretic hormone
secretion [35]; however, moderate limb and truncal ataxia
were additionally present in one of them. Given that PCA-
2 was frequently associated with other antibodies, such as
anti-Hu, anti-CV2/CRMP5, anti-neuron type AChR, anti-
VGCC of the P/Q type and anti-VGCC of the N type, it is
conceivable that some of those syndromes were not or not
exclusively caused by PCA-2-related autoimmunity.
In addition, PCA-2 were found in 1/58 patients with
newly diagnosed SCLC but no neurological symptoms at
the time of blood sampling [35].
CSF findings were reported for five patients and in-
cluded mild lymphocytic pleocytosis (n = 3; 18 and 9/μl,
1× non-specified) nd elevated total protein (n = 3, 51–
59 mg/dl); no data on the frequency of positive OCBs
are available [35].
Brain MRI was normal in two at first presentation, one
of whom later developed an abnormality in the left
medial temporal lobe consistent with encephalitis, and
was not reported in the other cases [35].
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With the exception of a single patient with unknown
tumour status, PCA-2 was associated with SCLC in all
cases reported so far [35]. Of note, in one of the three
patients with PCA-2-positive PCD, the diagnosis of
(limited) SCLC could only be made from a lymph node
biopsy 1 year after onset.
Outcome and prognosis
In one patient with PCA-2 and predominant cerebellar
disease, a first course of VP-16 and caroplatin chemo-
therapy was followed by marked improvement of
ataxia. In another patient improvement after therapy
with oral cyclophosphamide (100 mg/day) was noted.
In the third patient, the outcome was unknown. In the
patient with predominant limbic encephalitis andFig. 4 Binding of PCA-2-IgG from a patient with ACA to a formalin-fixed mou
cytoplasm of cerebellar granular cells (so-called ‘chicken-wire pattern’). A FITC
patient IgG. Image modified from Vernino S and Lennon VA. New Purkinje ce
autoimmunity. Ann Neurol 2000, 47:297-305; © 2000 by the American Neuroloconcomitant cerebellar ataxia, seizures ceased under
treatment with intravenous and oral steroids, but cog-
nition and balance continued to decline [35].
Antigen
The antigen targeted by PCA-2 is still unknown.
Immunohistochemistry
PCA-2 was reported to bind to mouse and human PC
dendrites and somata (sparing the PC nucleus) (Fig. 4).
In the original publication, it was not specified whether
PC axons were targeted as well. The cytoplasmic fluores-
cence was described as ‘reticular’ as opposed to the
coarse PC soma staining observed with anti-Yo (PCA-1)
and the punctuate staining seen with anti-Tr/DNER [35].
In addition, prominent staining of the cytoplasm (but notse cerebellum tissue section. Note the additional staining of the
-labelled anti-human IgG secondary antibody was used to visualize bound
ll antibody (PCA-2): marker of lung cancer-related neurological
gical Association; reprinted with kind permission from the publisher
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Finally, the cerebellar granular layer is stained by PCA-
2, yielding a faint ‘chicken-wire pattern’ not usually
seen with the other Medusa head antibodies discussed
in this review [35].
PCA-2 reportedly also stains neural elements in the
mouse gut smooth muscle and neuronal elements adja-
cent to and innervating arterioles in mouse kidney sec-
tions [35].
Whether anti-VGCC contributed to the PC staining in
those four patients with concomitant anti-VGCC was
not examined [35].
Antigen-specific immunoassays
As the antigen is unknown, no antigen-specific assays
exist. However, Western blotting of SDS-denatured rat
cerebellum protein extracts consistently revealed binding
of patient IgG to an unidentified 280-kDa protein in all
ten patients analysed [35].
CSF testing
CSF was analysed for PCA-2 in two patients, one of
whom had PCD. In both cases, relatively high CSF titres
as compared to serum were found, suggesting possible
intrathecal synthesis.
Association with other autoantibodies
In six out of the ten PCA-2-positive patients reported so
far, co-existing antibodies to P/Q-type VGCC (associated
in LEMS in 2/3), N-type VGCC, neuronal (ganglionic)
AChR and/or muscle AChR were present. Two out of
the six anti-VGCC-positive patients had cerebellar
ataxia, one of whom was in addition positive for anti-
CV2/CRMP5 [35].
Pathogenetic relevance
So far, no data on the pathogenic impact of PCA-2 exist.
Molecular genetics
The antigen of PCA-2 is currently unknown; accord-
ingly, no molecular genetic data exist.
Anti-Tr/DNER
Clinical, paraclinical and epidemiological features
The antibody was first described in 1976 by Trotter and
colleagues in a 21-year-old woman with subacute PCD
and Hodgkin’s disease (HD) [88]. The reactivity was
therefore later named anti-Tr (for Trotter) [36]. Graus
et al. [36] reported five patients (female:male = 1:4, me-
dian age, 36 years [range 14–72]) with anti-Tr, HD and a
subacute pancerebellar syndrome with mild to moderate
limb ataxia and moderate to severe truncal ataxia and
(mostly downbeat) nystagmus in all cases. Of note,
extracerebellar symptoms were present in two patients(1× extensor plantar response, 1× retrobulbar optic
neuropathy). In two cases, onset of disease was preceded
by febrile infection (1× flu-like, 1× tonsillitis). CSF
showed pleocytosis in all five cases (median 20 cells/μl
[range 12–102]). Brain MRI was normal at initial evalu-
ation but detected cerebellar atrophy in all cases at
follow-up.
Bernal et al. [50] described 28 patients (female:male =
1:3.6; median age, 61 years [range 14–75]) with anti-Tr,
some of whom had already been included in the previ-
ous study by Graus et al. [36]. While 25/28 had an
isolated cerebellar syndrome, two additionally had
encephalopathy and sensory neuropathy, and one
exclusively had symptoms (but no MRI changes)
compatible with limbic encephalitis. In 22 cases, the
cerebellar syndrome took a subacute and severe
course. LP revealed mild CSF pleocytosis in 13/22 patients
for whom data were available (median 50 cells/μl [range
14–150]). While the disease took a subacute course in
most cases, one patient had only mild, chronic cerebellar
ataxia.
A study by Probst et al. [89] tested 38 anti-Tr-positive
patients, many of whom may have been already in-
cluded in previous studies. Of those, 35 had PCD and
HD; the remaining samples included 1 patient with
PCD without a confirmed tumour, 1 with limbic en-
cephalitis and HD, 1 with paraneoplastic encephalomy-
elitis and HD, 1 with no neurological symptoms and 1
with missing data.
In a study by De Graaf et al. [87], all 11 patients
for whom data were available (7 male, 4 female,
median age, 50; range, 12–75) had subacute and se-
vere truncal and limb ataxia with nystagmus and/or
cerebellar dysarthria. Brain MRI showed cerebellar
atrophy only in 1/11 patients; another patient had
white matter lesions.
Tumour association
Anti-Tr/DNER antibodies are almost [90] exclusively found
in patients with HD. Only a few patients have been re-
ported in whom no HD (or any other tumour) was known
at the time of testing [50, 87, 89], although the follow-up
period was possibly too short in some to rule out a malig-
nancy with certainty [50]. Graus et al. [36] did not find
anti-Tr antibodies in 159 patients with cerebellar disorders
without HD. Similarly, Probst et al. [89] found no evidence
of anti-Tr/DNER in 25 patients with non-Hodgkin’s lymph-
oma—7 with breast cancer, 6 with non-SCLC, 3 with ovar-
ian cancer and 13 with other tumours—in neurological and
non-neurological patients without tumour or in healthy
controls. anti-Tr is also absent in patients with PCD and
non-Hodgkin’s lymphoma in another study [87]. Rarely,
anti-Tr may be present in patients with HD but no neuro-
logical symptoms [36, 87].
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tients included mostly nodular sclerosing HD but also
cases with mixed cellularity or, least commonly, lympho-
cyte depletion [36, 50, 87]. HD stages at the time of first
diagnoses ranged from I to IVA [36]. Limited HD (stage
I or II) was the most common finding (76 %) in one of
the largest series on anti-Tr-positive patients [50].
The diagnosis of PCD precedes the diagnosis of HD in
the vast majority of patients [36, 50, 87]. The median
time between PCD and HD diagnosis was 5 months
(range, 0–12), 3.5 months (range 0–24) and 4.2 months
in three independent studies [36, 50, 87]. However, PCD
may rarely also develop after tumour diagnosis (median
12 months; range 3–120); in such patients, anti-Tr-
positive PCD may predict HD recurrence [50].
Of special note, anti-Tr reportedly disappeared spontan-
eously in some patients without HD. Whether this was
caused by immune-mediated eradication of the tumour
(as sometimes observed in anti-Hu syndrome and SCLC)
or whether anti-Tr is of non-paraneoplastic (e.g. post-
infectious) origin in some cases remains to be elucidated.
Outcome and prognosis
In the index patient, radiation therapy for HD halted the
progression of the neurological disease. In the study by
Graus et al. [36] treatment with chemotherapy (in four) or
radiotherapy (in one) resulted in complete remission of
HD in all patients (median follow-up, 46 months; range,
12–52) and stabilization or remission of the neurological
symptoms. However, cerebellar atrophy was present in all
cases at last follow-up, and 4/5 patients were disabled due
to the cerebellar syndrome. One patient showed complete
remission within 2 months under treatment with cortico-
steroids. In the cohort of Bernal et al. [50], the cerebellar
syndrome was subacute and irreversible in 22/26 patients
(includes all three patients with anti-Tr but not tumour)
with poor functional outcome but showed a clear im-
provement in the remaining four, suggesting that the cere-
bellar damage is reversible in some instances. One patient
in that cohort stabilized following haematopoietic stem
cell autotransplant. Of note, complete remission of the
ataxia was found in 43 % of the patients under 40 years of
age, whereas only 5 % older than 40 years showed at least
partial remission [50].
In the study by de Graaf et al. [87], most patients
showed little (4/11) or no (6) improvement on the modi-
fied Rankin score after tumour therapy and, in five, im-
munotherapy (PEX and/or IVIG); one patient worsened
under treatment [87]. Complete tumour remission was
achieved in 10/11 cases and stable disease in one.
Antigen
DNER, the target antigen of anti-Tr [87], is a single-pass
type I transmembrane protein highly expressed in PCcell bodies and dendrites (but not axons) (Fig. 5) as well
as in numerous other neurons, including cortical and
hippocampal pyramidal neurons in mice [91]. Extracellu-
lar EGF repeats make it accessible to circulating anti-Tr.
The main antigenic epitope has been indeed mapped to
an extracellular 176-aa region between EGF domains 2
and 3. Some sera recognized a second epitope, which
was also located in the extracellular region of DNER,
but no differences in the clinical phenotype were noted
[87]. DNER has also been detected intracellularly in the
sorting endosomal compartment of dendrites and cell
bodies in various types of CNS neurons [91]. As a Notch
ligand activating the NOTCH1 pathway, it is thought to
mediate PC-Bergmann glial interaction during cerebel-
lar development [91–93]. Dner-knockout mice show
cerebellar hypoplasia, irregular CF and PF innervation
of PCs and lowered glutamate aspartate transporter
(GLAST) expression in Bergmann glia, resulting in re-
duced glutamate clearance at the PC-PF synapses. Func-
tionally, lack of Dner is associated with disturbed motor
coordination in the fixed bar and rotarod tests [93].
Moreover, cerebellar histogenesis is retarded in DNER-
knockout mice, resulting in overall size reduction, hypo-
plasia of the cerebellar fissure and folia, delayed layer
organization with significantly more remaining granule
cells in the extragranular layer and a thinner molecular
layer than in wild-type controls [93].
Immunohistochemistry
Anti-Tr were first identified by means of an indirect im-
munofluorescence assay employing unfixed human cere-
bellum tissue sections [88]. Graus et al. [36], in a study
aiming to immunologically characterize the anti-Tr re-
activity in more detail, used conventional IHC on
acetone-fixed human and rat cerebellum sections. Both
studies found labelling of the PC cell bodies and prox-
imal dendrites [36, 88]. However, anti-Tr are best char-
acterized by the fine dotted pattern they cause in the
molecular layer, which probably corresponds to staining
of small dendritic branchlets perpendicular to the plane
of the section (Fig. 6) [36, 94]. The PC axons are usually
spared [94]. The rat PC cytoplasmic staining pattern was
described as coarse granular [36, 94]. Neurons of the
deep cerebellar nuclei are only faintly positive [36, 50],
which is in contrast to the strong staining observed with
anti-Yo-positive sera [94]. While one study found no
binding to basket and stellate neurons [36], another one
did [94]. Bernal et al. [50] also located the punctuate
staining to dendritic branchlets in the molecular layer of
the cerebellum. Neurons of the granular layer are nega-
tive, except possibly in a few Golgi cells [36, 50, 94].
Of note, important differences in the extra-cerebellar
binding pattern of anti-Tr were found between rat and
human tissue [36]. In rat tissue, anti-Tr was found to
Fig. 5 Expression of DNER in the human cerebellum as demonstrated by IHC (modified image from the Human Protein Atlas image database [33])
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the dotted patterns observed in the cerebellum) to neu-
rons in the hilus of the dentate gyrus and the plexiform
layers of the hippocampus and to randomly distributed
neurons in the molecular layer and layers II and III of
the neocortex (but not to large neocortical projection
neurons), to neurons in the piriform and entorhinal cor-
tex, the lateral and basal amygdala, the trigeminal gan-
glia, the striatum, and less intensely, to neurons in the
reticular thalamic nuclei of the thalamus, in the di-
encephalon and in the brainstem [36, 87]. By contrast,
no anti-Tr immunoreactivity was observed in the large
neocortical projection neurons, in glial and ependymal
cells, in the choroid plexus and in the leptomeninges or
in extra-neuronal tissues such as liver, kidney, spleen,
thymus, adrenal cortex and testis.
In human tissue, anti-Tr only labelled PCs, in a pat-
tern similar to that of anti-Yo, but not neurons in other
CNS regions, including the cerebral cortex, hippocam-
pus, putamen, thalamus, mammillary bodies, lateral gen-
iculate body, substantia nigra and dentate nucleus [36].
The staining characteristic for anti-Tr is in line with
the distribution of DNER, which is highly expressed in
the PCs in a punctuate somatodendritic manner and has
been shown to be also present in isolated pyramidal hip-
pocampal neurons in rat brain sections [87, 91, 95].Besides IHC, immunocytochemistry (ICC) employing
primary hippocampal neurons has been used to demon-
strate anti-Tr seropositivity: co-localization of patient
IgG with a commercial anti-DNER antibody was taken
as evidence for anti-Tr positivity [87, 96].
Antigen-specific assays
De Graaf et al. [87] successfully used a CBA employing
formalin-fixed HeLa cells expressing full-length human
influenza haemagglutinin-tagged DNER and non-
transfected control cells to detect anti-Tr. This assay
yielded a sensitivity of 100 % (CI 95 % 69.9–99.2; 12/12
samples) and a specificity of 99.59 % (95 % CI 97.4–
100; 1/246 control samples). Of note, the only positive
control serum was obtained from a patient with HD
but no neurological symptoms and also showed anti-Tr
positivity when tested by IHC. An independent study
used both DNER-transfected HEK293 cells and HeLa
cells as antigenic substrates to detect anti-Tr/DNER in
6 patients with HD. In that study, the use of living instead
of fixed, permeabilized, transfected cells resulted in an im-
proved signal-to-noise ratio [96]. Very recently, a commer-
cial CBA using formalin-fixed HEK293 cells transfected
with full-length human DNER and mock-transfected as
well as CDR2/Yo and CDR2L-transfected cells as control
substrates has been described, which yielded a sensitivity of
Fig. 6 Binding of IgG from a patient with anti-Tr/DNER-associated ACA to a rat cerebellum tissue section. A goat anti-human IgG secondary antibody
labelled with fluorescein isothiocyanate (green fluorescence) was used to visualize bound patient IgG
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samples and a specificity of 100 % (95 % CI 98.7–100 %)
based on 201 control samples [89].
Anti-Tr has also been detected by using wild-type
hippocampal pyramidal neurons and neurons in which
anti-Tr was knocked down with shRNA constructs
[87]; accordingly, cerebellum sections from wild-type
and DNER knock-out mice could be used as substrates
for anti-Tr testing.
De Graaf et al. [87] mapped the main epitope to an N-
glycosylated extracellular region of DNER. This was re-
cently confirmed in an independent study reporting a
lack of anti-Tr staining after preincubation of sera with
the extracellular domain of DNER [89]. This is import-
ant for the development of future immunoassays for
anti-Tr/DNER.
Of note, N-glycosylation mutations abolishes the anti-
Tr staining, indicating that glycosylation of DNER is
required for detecting anti-Tr [87, 95].Knock-down of DNER by transfection with short hair-
pin RNA-producing constructs eliminated anti-Tr stain-
ing in hippocampal neuron culture, proving that DNER
is the only antigen of anti-Tr. Moreover, preadsorption
IHC experiments have been successfully applied. Incuba-
tion of anti-Tr sera with either biotinylated GFP-DNER
coupled to streptavidin beads, recombinant full-length
DNER or its extracellular domain prior to IHC re-
sulted in a loss of anti-Tr-specific staining in two re-
cent studies [87, 89].
Immunoblots of isolated PCs or mouse cerebellum ho-
mogenates have been attempted but failed to identify a
common band both under reducing and non-reducing
conditions [36, 97]. Similarly, Western blotting with
either total extracts from HEK293 cells expressing HA-
DNER or purified HA-DNER from HEK293 cells was
unreliable for diagnosing anti-Tr [87]. Of 12 anti-Tr-
positive sera tested, only 3 came up positive in the total
extract-WB and only 11 in the purified DNER-WB.
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confirm that sera showing such binding patterns target
the same antigen as previously identified sera [50].
Abolished binding of a biotinylated anti-Tr-positive
immunoglobulin G (IgG) from an index patient by pre-
incubation with undiluted serum from a patient with
anti-Tr-like binding on rat cerebellum sections was
taken as evidence for epitope identity [50].
CSF testing
Anti-Tr antibodies are mostly produced intrathecally as
indicated by an elevated Tr-specific antibody index [36].
Of note, Bernal et al. [50] reported two rare cases (2/28;
7 %) in which the antibody was detected only in the CSF
but not in the serum; however, a high screening serum
dilution of 1:500 was used. As expected, CSF samples
from anti-Tr-positive patients were shown to recognize
DNER [87, 96].
Association with other autoantibodies
Antibodies to DNER were not found in 70 samples posi-
tive for either anti-Hu, anti-Yo, anti-Ri, anti-Ma, anti-
amphiphysin or anti-CV2/CRMP5 [87]. Anti-DNER was
also negative in 30 patients with systemic lupus erythe-
matosus or rheumatic arthritis [87]. All anti-Tr sera
tested by Graus et al. [36] were negative for anti-Hu, -Yo
and -Ri antibodies, and none of the control sera with
anti-Yo or other anti-Purkinje cell antibodies was posi-
tive for anti-Tr.
Pathogenetic relevance
The main epitopes of anti-Tr/DNER have been mapped to
an N-glycosylated extracellular region of DNER by using
deletion constructs and a glycosylation inhibitor [87]. Ac-
cordingly, binding of anti-Tr/DNER to non-permeabilized,
living hippocampal neurons, which naturally express
DNER on their surface, has been demonstrated [87, 96],
rendering a direct pathogenic effect of anti-Tr/DNER at
least possible. Alternatively, cerebellar damage in Tr/
DNER might be caused by DNER-specific T cells.
The observation of severe PC loss in an anti-Tr-
positive patient with ACA (but no tumour) in the ab-
sence of any significant cellular infiltrates suggests that
anti-Tr potentially has a pathogenic impact [50]. Histo-
pathology revealed only sporadic T cells and macro-
phages but a total loss of PCs accompanied by mild
Bergmann gliosis. In addition, mild secondary neuronal
cell loss with gliosis was noted in the dentate nucleus
and inferior olive. In line with that finding, ataxia is irre-
versible or shows only little improvement in many anti-
Tr-positive patients [87].
Further indirect findings in favour of a pathogenic
role of anti-Tr include the strong association of anti-
Tr with ataxia in patients with HD, with the antibodybeing virtually absent in patients with HD and no
PCD, the intrathecal synthesis of anti-Tr, the observa-
tion that DNER knockout causes ataxia in mice, and
from the predominance of complement-activating
IgG1 and IgG3 antibodies among anti-Tr subclasses
(which may suggest a Th1-type response of CD4+ T
helper cells). All five patients reported by Graus et al.
[36] were positive only for Tr-IgG (detectable also by
anti-human kappa and lambda) but not for Tr-IgM.
Bernal et al. [50] found anti-Tr-IgG1 (4/17) or -IgG3
(4) or both (9) in all tested sera. Two sera with anti-
Tr-IgG2 or -IgG4 were also anti-Tr-IgG1 positive;
again, no anti-Tr-IgM was detected [50].
On the other hand, no obvious abnormalities in morph-
ology were observed in either cerebellar organotypic or
primary hippocampal neuron cultures upon incubation
with anti-Tr-positive sera [87]. However, it is unclear
whether the cells were incubated together with hu-
man complement as required for antibody-dependent
complement-mediated cytotoxicity, which has been
shown to be the major pathogenetic mechanism in
other antibody-mediated autoimmune disorders of the
CNS such as NMO [98–100].
The relationship between HD and anti-Tr autoimmun-
ity is not well understood. While most patients have
HD, anti-Tr have also been described in some patients
without tumour (follow-up time up to 3 years) [50].
Moreover, anti-Tr normally do not bind to pathological
lymph nodes from patients with HD [36, 50] and, ac-
cordingly, DNER expression seems to be absent in HD
tissue. A role of ectopic DNER expression as a disease
trigger is thus unlikely.
Taking into consideration that HD may promote T-cell
dysfunction, resulting in an increased risk for viral infec-
tion [36, 101], that HD is often associated with polyclonal
B cell activation [102], and the observation that anti-Tr-
related PCD was indeed preceded by febrile infections in
some patients, a possible parainfectious origin of anti-Tr
in the context of HD-related immune dysregulation has
been proposed as an alternative explanation [50, 87].
Of note, successful treatment of HD is accompanied
by disappearance of anti-Tr [50]. In addition, spon-
taneous disappearance in patients without tumour has
been observed [50], which is different from what has
been reported in patients with anti-Hu and anti-Yo
antibodies [103–105].
Molecular genetics
So far, no association of SCA with mutations in the
DNER gene has been reported in humans.
Medusa head antibodies of unknown specificity
Over the past 4 years, we have seen a number of samples
that showed a Medusa head pattern when tested by IHC
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anti-ITPR1, anti-CARP VIII, anti-Ca/ARHGAP26, anti-
GluRδ2, anti-Yo and anti-Tr/DNER when tested using
commercial CBAs (Euroimmun) nor displayed the add-
itional IHC and WB features reported for PCA-2 or anti-
PKCγ. As some of those samples yielded high titres, it is
unlikely that sensitivity issues underlie this observation in
all cases. This suggests that antibodies to further somato-
dendritic PC antigens may exist.
Other autoantibodies associated with ACA
Several other anti-neuronal and anti-glial autoanti-
bodies have been reported in association with cerebel-
lar ataxia. However, the immunostaining observed with
those antibodies differs significantly from that described
above in that they do not bind in a somatodendritic
pattern.
While some of those antibodies bind to neuronal
nuclei (anti-Hu, anti-Ri, anti-ANNA3) or nucleoli
(anti-Ma2/Ta), most bind to cytoplasmic or plasma
membrane-bound antigens. Staining of intestinal tissue
sections can be helpful when it comes to discriminating
these antibodies. While Hu antibodies also bind to the
cell nuclei of the plexus myentericus neurons, Ri anti-
bodies do not.
Anti-GAD antibodies are characterized by strong
binding to the granular layer. Anti-amphiphysin, anti-
DPPX and anti-GABABR antibodies show a similar pat-
tern to that of anti-GAD antibodies, but in addition
react with the neuropil of the molecular layer while spar-
ing the PC somata. While anti-amphiphysin tend to stain
more strongly the molecular layer than the granular
layer, the opposite is true for anti-DPPX antibodies
[106–108]. The binding pattern of anti-GABABR is less
well defined since sera may react either with pre-
synaptic receptors located on PF or with post-synaptic
receptors present on PC fibres, or both. In addition, the
two anti-voltage-gated potassium channel (VGKC)-com-
plex antibodies CASPR2 [109, 110] and LGI1 [111] have
both recently been implicated in ACA.
Anti-glial cell reactivities include antibodies to AQP4,
the most important laboratory marker of NMO [112,
113], and so-called anti-Bergmann glial cell nuclear
antibodies (AGNA), which are considered markers of
lung cancer. Manifestations of AQP4-Ab-positive NMO
only rarely include cerebellar symptoms, some of which
are caused by lesions in the cerebellar pedunculi.
AQP4-IgG bind in a very characteristic pattern to astro-
cytic endfeet adjacent to the blood vessels, Virchow
Robin spaces and pia mater. In addition, chicken-wire-
like staining of the granular layer can be present, prob-
ably corresponding to the astrocytic sheath of cerebellar
glomeruli. Anti-SOX1 is a marker of SCLC and was ori-
ginally thought to be identical to AGNA antibodies,while recent observations rather suggest a co-reactivity
of two independent antibodies.
Anti-CV2/CRMP5 is a common reactivity in patients
with paraneoplastic neurological disorders and typically
produces a ‘sand-like’ staining pattern, most prominently
in the cerebellar white matter.
Antibodies to transglutaminase 6, which some authors
consider a frequent cause of cerebellar ataxia that
possibly can be treated by gluten-free diet [114, 115],
are not normally diagnosed by IHC.
Furthermore, a number of (so far mostly unconfirmed)
post-infectious antibodies have been described in the
literature, including anti-centrosome antibodies (anti-γγ-
enolase, anti-pericentrin, anti-ninein, anti-PCM1 and
anti-Mob1) in patients with post-varicella ACA [116],
anti-centriolar antibodies in post-Mycoplasma pneumo-
niae ACA [117] and antibodies to triophosphate in pa-
tients with post-Epstein-Barr virus ACA [118].
Finally, an anti-GD1b IgG-associated, atactic Guillain-
Barré syndrome subvariant has been proposed [119–121];
however, its nosological status as a cerebellar disorder is
controversial [122].
Diagnostic pitfalls and limitations
While IHC is an important screening method when it
comes to testing patients for anti-neural antibodies, its
specificity is limited.
First, the IHC staining patterns described for the 12
‘Medusa head’ antibodies discussed above are rather
similar. Accordingly, it is difficult for the non-expert
rater to correctly distinguish the various patterns, espe-
cially at the lower magnification often employed in rou-
tine diagnostic laboratories. The use of additional tissues
may facilitate differentiation of the various antibodies.
Second, co-existing autoantibodies present in the pa-
tients’ serum or CSF may alter the typical binding pat-
terns described above. Anti-neural antibodies may either
occur in association with other anti-neural antibodies or
with non-CNS-specific, pathogenic or non-pathogenic
(e.g. naturally occurring) systemic autoantibodies. This
can produce atypical staining patterns and may delay
making the correct diagnosis. For example, ANA, which
are frequently present even in healthy subjects, can
cause staining of the interneurons of the molecular layer,
a feature not present with anti-Ca/ARHGAP26, anti-Sj/
ITPR1 and other known PC antibodies, resulting in
atypical IHC patterns. This underlines the importance of
additional antigen-specific testing. In some cases, use of
CSF instead of serum or titration of serum or CSF
samples may reduce confusing co-staining by co-existing
antibodies. However, titration may also result in the loss
of diagnostically important details if antigen concen-
trations vary between cells or subcellular structures. For
example, axons are less strongly stained by anti-
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if sera are diluted. Alternatively interference by non-
CNS-specific antibodies can be reduced or eliminated by
pre-adsorption with acetone liver powder [112, 123,
124], a rather crude procedure that may also result in a
loss in sensitivity.
Third, binding patterns on cerebellar tissue sections
may vary between species. For example, anti-Tr antibodies
have been found to bind to both human and rat cerebel-
lum but exclusively to rat hippocampus [36, 125]. Simi-
larly, many other rat brain tissues stained by anti-Tr are
not reactive if human tissue is used. Differences between
species have also been observed with anti-Yo [34, 39, 126].
Fourth, tissue morphology can differ substantially de-
pending on sectional planes, which can be confusing for
raters not familiar with the complex cerebellar cyto-
architecture (Fig. 7).
Fifth, IHC binding patterns may depend on techniques
used for tissue preservation/fixation, which can critically
alter target antigen confirmation, and antigen retrieval.
For example, anti-CARP VIII were only detected on fro-
zen tissue sections but not on paraffin-embedded sections
[127]. Using thin tissue sections, intracellular antigens can
usually be detected without a need for cell permea-
bilization since most PCs will be transected. Similarly,
some CBAs strongly depend on fixation.
Sixth, expression levels of some antigens differ between
PC somata, dendrites and axons. In consequence, struc-
tures which contain only low levels of the respective anti-
gen, in particular the PC axons, might not get stained by
low titre samples or when samples are tested at high dilu-
tion (e.g. to reduce background staining).
Given those limitations, IHC testing should ideally be
followed by antigen-specific testing, even if results are
prima facie considered typical. In addition to immunoblot
assays, CBAs are increasingly being used to detect anti-
neuronal antibodies. While solid data on the sensitivity of
IHC testing for most of the anti-PC antibodies discussed
here are lacking, recombinant assays have been shown to
be more sensitive than IHC in some other autoantibody-
associated diseases of the CNS [128]. A very recent study
found a higher sensitivity of an anti-Tr/DNER-specific
CBA in a direct comparison with IHC [89].
Competitive IHC based on abolition of patient IgG
binding by preincubating the respective diagnostic sub-
strate with a strongly binding positive reference serum
[50] as well as pre-adsorption of patient sera with recom-
binant antigen have both been successfully used to con-
firm antigen specificity [129, 130]. IHC is not routinely
used for detecting anti-VGCC, which are usually tested
for by RIA with native protein as antigenic substrate.
As very low-titre antibodies might not be detectable
by IHC, it may be recommendable to use antigen-
specific assays in IHC-negative cases, too. However, itmust be kept in mind that the diagnostic specificity of
some of the currently available antigen-specific immuno-
assays, many of which are in-house assays, has not been
evaluated in sufficiently large cohorts and false-positive
results cannot be excluded.
In the case of discrepant results between IHC and
antigen-specific testing, a third, methodologically inde-
pendent assay should be used. In addition (or alterna-
tively, if no third method is available), follow-up testing
should be considered, though this may not rule out
false-positive results caused by systematic confounders
related to the respective detection method.
Titres may decline after PEX, immunosuppressive or
steroid treatment, or chemotherapy for cancer and may
temporarily drop below detection limits. Re-testing later
in the disease course is therefore recommended in ‘sero-
negative’ cases if initial testing was done during periods
of active treatment.
As discussed above, more autoantibodies to PCs
may exist than known to date. Accordingly, negative
test results obtained with recombinant assays in pa-
tients with ‘Medusa head ataxia’ do not necessarily
indicate insufficient sensitivity of the respective assay;
instead, the antibodies might target a so-far unknown
antigen.
Many immunoassays, including IHC and CBAs, are
rarely affected by the so-called high-dose hook effect
(HDE), which results in false-negative or falsely low re-
sults when low dilutions are used. While that effect is
thought to be caused by a saturating excess in antigen
concentration in ELISA preventing sandwich or bridge
formation, the cause of HDE in IHC and ICC is less well
understood. It has been speculated that HDE in IIF
might be caused by anti-immunoglobulin conjugates
being unable to reach their antigenic determinants on
tightly clustered immunoglobulin molecules [112, 131].
Samples should therefore be tested at two or more dif-
ferent dilutions.
Finally, it should be kept in mind that some of the PC
antibodies reported so far were identified by screening
of pre-selected cohorts of patients with ACA. Moreover,
some of the identified target antigens are expressed out-
side the cerebellum as well. Accordingly, the full
spectrum of clinical signs and symptoms associated with
those antibodies may expand in the future when more
patients become tested. Similarly, a broader spectrum of
symptoms than initially thought has been found in many
other antibody-associated diseases of the CNS over the
past few years [106, 110, 113, 132–135]. In consequence,
the presence of signs or symptoms other than cerebellar
ataxia does not per se argue against the validity of a
given test result.
That said, it is important to consider that the ratio of
false-positive to true-positive results found with any test
Fig. 7 IHC patterns strongly depend on sectional planes and tissue donor species. a, b Binding of a commercial Homer-3 antibody to different
sectional planes of human cerebellum tissue (modified images from [33]). c, d Binding of human IgG from a patient with ITPR1-Ab-positive ACA
to mouse (c) and monkey (d) PC dendrites, respectively, sectioned at different planes. e, f Anti-Yo IgG antibodies as detected by use of primate
(e) and mouse (f) cerebellum tissue sections, respectively, sectioned at different planes
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have the respective disease. In order to limit the risk of
false-positive results, we therefore do not currently
recommend testing routinely for any of the antibodies
reviewed here using recombinant assays in indications
other than those outlined above, unless qualitative
evidence from IHC assays clearly indicates the presence
of antibodies to PCs.Differential diagnoses
While autoantibody-associated autoimmunity is an im-
portant differential diagnosis in patients presenting with
signs or symptoms of cerebellar ataxia, other causes
need to be considered as well. These include the many
forms of hereditary ataxia as well as toxic (including
chemotherapy-related), infectious and vascular diseases
of the cerebellum. In addition, other forms of ACA have
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tiple sclerosis, MOG-IgG-related autoimmunity, (very
rarely) neuromyelitis optica, rheumatic disorders and
vasculitis, Behçet disease, ADEM and post-infectious
cerebellitis with presumed T cell-mediated pathogenesis,
and sarcoidosis. An overview of autoantibodies to neur-
onal or glial cells other than PCs that have been re-
ported in patients with ACA is given in Table I in the
first part of this article series.
Summary and outlook
The past few years have seen the discovery of a multi-
tude of new autoantibodies and autoantigens in patients
with cerebellar ataxia. Many patients previously diag-
nosed with ‘idiopathic ataxia’ can now be given a more
definite diagnosis. Of note, some of these novel reactiv-
ities not only indicate an autoimmune pathogenesis but
were also shown to predict a facultative or obligate para-
neoplastic aetiology.
While in some disorders, such as anti-mGluR1 and
anti-VGCC ACA and, possibly, anti-GluRδ2 ACA, evi-
dence for a directly pathogenic role of the antibody exists,
it is unknown in others whether the antibody itself is
harmful or only an epiphenomenon of diagnostic rather
than pathogenic relevance. Alternatively, a T cell-mediated
immune response may cause damage to the cerebellum in
those disorders.
It has been argued that antibodies to intracellular anti-
gens (as opposed to antigens expressed on the cell sur-
face) are likely not directly involved in the pathogenesis
of ACA since they may not be capable of reaching their
target antigens. However, passive transfer experiments,
which could only prove that hypothesis, have not yet
been performed in many of those syndromes. Moreover,
uptake of human [32, 54–59, 136–138] as well as mouse
[139] IgG by PCs has been described in numerous stud-
ies. Given that most of the intracellular antigens targeted
by those antibodies are linked to calcium homoeostasis
as outlined in this article, which is crucial for many cell
functions and dysregulation of which may result in cell
death, including by apoptosis [140], a direct effect of
antibodies to intracellular antigens on cell function and
survival cannot be fully ruled out. Incorporation of anti-
CDR2 and CDR2L antibodies (anti-Yo) has recently in-
deed been reported to affect PC calcium homoeostasis
[32] and to cause defective PC arborization [32] and PC
cell death in cultured PCs [57], though confirmatory
studies are certainly needed.
Moreover, antibodies against intracellular antigens
have been previously shown to be of pathogenic impact
in syndromes other than ACA. Injection of human
serum containing high titres of antibodies to amphiphy-
sin, a protein associated with the cytoplasmic surface of
synaptic vesicles, was found to cause dose-dependentstiffness, with spasms resembling human stiff-person
syndrome in rats [141–143] as well as anxiety behaviour
[144]. IgG to amphiphysin was shown to be internalized
by neurons and to alter the function of inhibitory synapses
in vivo [142]. Amphiphysin is also a known autoantigen in
PCD. These findings might potentially be of relevance also
for ARHGAP26-related ACA. ARHGAP26 and amphiphysin
are both involved in endocytosis, and anti-ARHGAP26
has been shown to co-precipitate dynamin, an import-
ant binding partner of amphiphysin, from mouse and
rat cerebellum or brain extract [130, 145]. Similarly,
antibodies to recoverin have been demonstrated to
enter retinal cells, probably by endocytosis, where they
induce caspase-dependent apoptosis [146]. A pathogenic
effect has also been proposed for antibodies to the intra-
cellular antigen glutamate decarboxylase 65 (GAD65)
[147, 148]. Finally, endocytotic uptake of antibodies has
also been found for cell types other than PCs and for a
subset of anti-DNA antibodies [149–152].
Interestingly, PCs have been reported to incorporate
IgG and IgM irrespective of the immunoglobulin’s re-
activity with Purkinje cell surface antigens [56], abolish-
ing the need for surface expression as a prerequisite of
antibody uptake.
The fact that so many novel autoantigens have been
detected over the past few years and the finding of PC-
specific staining in a substantial number of patients with
ACA negative for all currently known antibodies renders
it likely that the future will see the identification of even
more target proteins in this condition. This offers great
diagnostic opportunities but poses also many new
diagnostic challenges: While IHC was previously the
mainstay when it came to diagnosing anti-neuronal anti-
bodies, when anti-Yo and anti-Tr were the only clinically
relevant somatodendritic PC reactivities, the increasing
number of known autoantibodies staining PC somata and
dendrites has made the use of recombinant assays crucial.
Each of these assays has its specific advantages and disad-
vantages and needs to be carefully evaluated—also in
comparison with other assays. Given the broad spectrum
of methods that can be used for detecting autoantibodies,
developing recombinant immunoassays that are both suf-
ficiently sensitive and specific and feasible for routine clin-
ical use can be an ambitious endeavour as exemplified by
the changeful and troublesome history of MOG-IgG
testing in multiple sclerosis and related disorders. This
is all the more true in conditions of (obligately or fac-
ultatively) paraneoplastic origin, in which false-negative
results may cause a significant delay in tumour diagnosis
and treatment and in which false-positive results may
submit patients to unnecessary and potentially harmful
diagnostic procedures. Given the multitude of in-house
assays currently used for diagnosing ACA-associated
autoantibodies, the development of standardized assays
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highly warranted.
In summary, autoantibody-associated ACA is a dis-
order that was probably underdiagnosed in the past. The
discovery of PC-specific autoantibodies has shed new
light on the pathogenesis of ACA, and the development
of recombinant assays has facilitated the early and spe-
cific diagnosis, and thus therapy, of this rare but often
devastating condition.
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